Cold Spring Harbor Laboratory (CSHL) and the North Shore-LIJ Health System have entered a strategic affiliation.
The agreement aligns CSHL’s world-class cancer research with North Shore-LIJ’s clinical research and growing network of clinical cancer services, within a health system that touches more than 16,000 individuals with newly diagnosed cancer annually.
The new partnership will benefit from the investment of more than $120 million to accelerate cancer research, diagnosis and treatment. The funds will be used to advance cancer therapeutics research, develop a new clinical cancer research unit at the North Shore-LIJ Cancer Institute’s headquarters in Lake Success to support early-phase clinical studies of new cancer therapies, and recruit and train more oncology clinician/scientists.
“This is a transformative affiliation for both institutions, bringing the cutting-edge basic discovery science and translational cancer research at CSHL to one of the largest cancer treatment centers in the United States,” said Bruce Stillman, PhD, CSHL’s president and CEO. “The unique integration of research scientists, clinical translational researchers and cancer clinicians promises to speed the advance of novel cancer diagnostics and therapeutics to patients in the region.”
“Bringing the scientists of Cold Spring Harbor Laboratory together with the more than 200 academic oncologists and clinicians of the North Shore-LIJ Cancer Institute will transform our approach to cancer research and treatment,” said Michael Dowling, North Shore-LIJ’s president and CEO. “North Shore-LIJ oncologists will make CSHL’s promising preclinical research available as innovative trials to select cancer patients at a much earlier stage. This will build on the clinical and translational research programs the health system has been offering its patients for more than 30 years and establish our Cancer Institute as a destination for pioneering cancer therapies.”
The CSHL/North Shore-LIJ affiliation will attract cancer researchers and clinicians to the region. As part of the collaboration, clinician/scientists will be trained to perform preclinical cancer research and conduct early-stage clinical trials. Positive findings from this research and therapeutics partnership will form the basis for advanced-phase clinical trials to be conducted at North Shore-LIJ facilities and collaborating outside medical centers. Patients cared for within the North Shore-LIJ Cancer Institute network will benefit from increased access to these innovative clinical studies.
Clinicians and researchers are working to better understand why some cancer patients respond well to certain treatments and some do not, said Daniel Budman, MD, director of translational research for North Shore-LIJ’s Division of Hematology and Medical Oncology.
“We’re recognizing more and more that cancer is not a monolithic disease,” Dr. Budman said. “A tremendous diversity of patients with different genetic backgrounds, ages and disease types comes to the Cancer Institute network. Integrating our resources with Cold Spring Harbor Laboratory will allow the researchers to do cutting-edge work to determine patients’ genetics and how that could affect their response to the cancer type and to a particular drug.”
The new clinical research collaboration distinguishes the North Shore-LIJ Cancer Institute from other cancer centers for its ability to deliver new therapeutics to cancer patients while also meeting the comprehensive medical and surgical needs of those afflicted with and at risk of the disease. Every year, North Shore-LIJ cares for more than 16,000 new cancer cases, giving patients access to the services of more than 200 physicians in over 25 subspecialties.
As one of the first research institutes to join the nation’s War on Cancer in the early 1970s, CSHL has made seminal discoveries that have helped diagnose and treat cancer patients, including the discovery of the first human cancer gene in 1982. The CSHL Cancer Center has been a National Cancer Institute-designated Cancer Center since 1987, and is the only such center on Long Island.
“Cold Spring Harbor Laboratory has developed a pipeline of preclinical drugs over the years,” said Dr. Budman. “Now, the Cancer Institute will be able to offer these potential breakthroughs to our patients.”